|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Fisogatinib (BLU-554) is a potent and selective inhibitor of FGFR4 and demonstrates clinical benefit and tumor regression in patients with HCC with aberrant FGF19 expression.
|
31575540 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BLU-667 attenuated RET signaling and produced durable clinical responses in patients with <i>RET</i>-altered tumors, clinically validating selective RET targeting.<i>Cancer Discov; 8(7); 836-49.
|
29657135 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, BLU suppressed tumor formation by strengthening the antitumor immunity.
|
28029652 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The mRNA level of UBE2N is increased in HCC tumors or cell lines.
|
29371970 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In current studies, we find that 93.5% of early-stage primary NPC tumors show downregulated BLU expression.
|
25347745 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BLU is a candidate tumor suppressor gene, which is epigenetically inactivated in many human malignancies.
|
26043875 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor suppressor BLU promotes paclitaxel antitumor activity by inducing apoptosis through the down-regulation of Bcl-2 expression in tumorigenesis.
|
23628417 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor suppressor BLU enhances pro-apoptotic activity of sMEK1 through physical interaction.
|
22349239 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor suppressor gene BLU is frequently downregulated by promoter hypermethylation in myelodysplastic syndrome.
|
22246278 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor suppressor BLU inhibits proliferation of nasopharyngeal carcinoma cells by regulation of cell cycle, c-Jun N-terminal kinase and the cyclin D1 promoter.
|
22727408 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BLU was recently characterized as a novel tumor suppressor gene (TSG), and was epigenetically silenced in some tumor cell lines and primary tumor samples.
|
20394502 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor suppressor gene (TSG) RASSF1A and candidate TSG BLU are two tandem head-to-tail genes located at 3p21.3.
|
20877461 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thirteen genes were analyzed for DNA methylation: the pro-apoptotic CASP8, CASP3, CASP9, DcR1, DR4, DR5 and TMS1; the cell adherence CDH1 and CDH13; the candidate tumor suppressor RASSF1A and BLU; the cell cycle regulator CHFR and the DNA repair MGMT.
|
17272309 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, no functional studies have yet verified the functional role of BLU/ZMYND10 as a tumor suppressor gene.
|
16929489 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Reduced expression of BLU was detected in some ESCC cell lines and tumor tissues and the difference was quantitated by real-time quantitative polymerase chain reaction.
|
15885884 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
On the other hand, some tumor-suppressor genes such as EPHB6, visinin-like protein 1 (VSNL-1), and BLU were up-regulated in MIF-reduced cells.
|
16314559 |
2005 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Hypermethylation of the RASSF1A promoter occurred in 47% (83/178) and of the BLU promoter in 43% (68/160) of NSCLC tumors examined.
|
15540210 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Previously, the RASSF1A, BLU and SEMAPHORIN 3B (SEMA3B) candidate tumor suppressor genes on chromosome 3p21.3 were found to be inactivated and downregulated by genetic and epigenetic changes in lung cancer.
|
15704097 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CACNA2D2 and SEMA3B were not frequently methylated, but the BLU gene located just centromeric to RASSF1 was frequently methylated in glioma cell lines (7/7) and in 80% (35/44) of glioma tumors.
|
14743209 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Ectopic expression of BLU results in the inhibition of colony formation of cancer cells, suggesting that BLU is a tumor suppressor.
|
15122337 |
2004 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The high incidence of BLU alterations suggests that it may be one of the critical tumor suppressor genes on chromosome 3p21.3 involved in the development of NPC.
|
12794757 |
2003 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
To elucidate the role of BLU in tumorigenesis, we analysed BLU promoter methylation status in tumour cell lines and detected promoter region hypermethylation in 39% lung, 42% breast, 50% kidney, 86% neuroblastoma and 80% nasopharyngeal (NPC) tumour cell lines.
|
12629521 |
2003 |